DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Stocks to watch: Airtel, Titan, Blue Dart, Gland Pharma, ONGC, Britannia

Business Standard 1 hr ago·6 Nov 2026, 2:35 am

Gland Pharma is set to release its second-quarter financial results for fiscal year 2027. This update will provide investors with a detailed look at the company's performance over the past three months, including its revenue, profit, and operational efficiency.

The earnings report is a key event for the pharma sector, as it offers insight into the company's growth trajectory and market positioning. Investors will closely watch for updates on sales, margins, and any strategic shifts that could impact future performance.

Moving forward, market participants will focus on the management's commentary regarding the current business environment and their outlook for the coming quarters. This information will be crucial for assessing the stock's potential in the near term.